z-logo
open-access-imgOpen Access
Shiga Toxin/Verocytotoxin-Producing Escherichia coli Infections: Practical Clinical Perspectives
Author(s) -
T. Keefe Davis,
Nicole C. A. J. van de Kar,
Phillip I. Tarr
Publication year - 2014
Publication title -
microbiology spectrum
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.502
H-Index - 51
ISSN - 2165-0497
DOI - 10.1128/microbiolspec.ehec-0025-2014
Subject(s) - verocytotoxin , escherichia coli , serotype , shiga toxin , medicine , antibiotics , intensive care medicine , disease , microbiology and biotechnology , asymptomatic , shiga like toxin , asymptomatic carrier , immunology , biology , enterobacteriaceae , gene , biochemistry
Escherichia coli strains that produce Shiga toxins/verotoxins are rare, but important, causes of human disease. They are responsible for a spectrum of illnesses that range from the asymptomatic to the life-threatening hemolytic-uremic syndrome; diseases caused by E. coli belonging to serotype O157:H7 are exceptionally severe. Each illness has a fairly predictable trajectory, and good clinical practice at one phase can be inappropriate at other phases. Early recognition, rapid and definitive microbiology, and strategic selection of tests increase the likelihood of good outcomes. The best management of these infections consists of avoiding antibiotics, antimotility agents, and narcotics and implementing aggressive intravenous volume expansion, especially in the early phases of illness.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom